Tagged with access,

Poland Dorota Hryniewiecka-Firlej, president of Pfizer Poland, discusses the current state of the Polish innovation landscape and importance of a tight-knit relationship between the innovative pharmaceutical market and the government for better patient outcomes. Furthermore, she highlights the strong R&D footprint of Pfizer Poland and their role in facilitating a domestic…

Serbia Between 2010 and 2012 just one of the 139 new medicines to receive market authorisations globally was approved for reimbursement in Serbia, compared with 44 in Bulgaria and 27 in Croatia; meaning a severe lack of patient access to much-needed treatments as well as an extremely challenging environment for innovative…

Poland Iwona Skrzekowska-Baran, owner and CEO of Pharm&Med, a young, exciting Polish consultancy that is helping clients to transform evidence, policy insights, and market intelligence into effective market access strategies. She highlights the niche approach of the company to the marketplace, challenges in Polish healthcare and the future aspirations of Pharm&Med…

Serbia Nebojsa Skuljec has held various positions in MSD Healthcare across the Balkans before his promotion to country lead for Serbia and Balkans emerging markets 14 months ago. In this interview Skuljec tells the story of MSD’s journey from humble origins to one of the big pharma players in Serbia, growth…

Poland Leonardo Maffioli, senior marketing and commercial manager of the fertility and endocrinology division of IBSA, discusses the story of IBSA Poland and the potential of the Polish market for the company. Furthermore, he highlights the market challenges of the country, especially for fertility treatments during a period of a conservative…

Canada Sylvie Bertrand, general manager of BSN medical Canada, an Essity company, highlights the value proposition BSN medical’s products bring to Canadian patients in chronic venous insufficiency, diabetic foot ulcers and lymphedema, and how the company contributes significantly to the sustainability of the Canadian healthcare system by focusing on the continuum…

India Nikhil Masurkar, executive director of Entod Pharmaceuticals, talks about the company’s ambition to invest in stem cell research and become market leaders in the field of ophthalmology in ten years’ time by adding more cost-effective and highly effective dosage forms to their strong product portfolio. Can you briefly introduce your…

Lithuania Martynas Jocys, Baltics marketing director and Lithuania general manager at AstraZeneca, talks about the role that innovation has played in the company’s strategy, the need for increased patient access in Lithuania and the other Baltic countries as well as the launch of new products for oncology, biologics, severe asthma, diabetes,…

Serbia By reorganizing their management structure, diversifying their offering and presenting an altogether cleaner image, AstraZeneca Serbia has made tremendous progress since its beginnings in the Balkans in the late 1990s. Country Director Ksenija Purkovic discusses the future of the Anglo-Swedish outfit, and how best to navigate a market that is…

Switzerland With two billion people globally – predominantly in low and middle-income countries – having little or no access to medicine, a select group of service providers have emerged to try and further dialogue between pharmaceutical companies, regulators, healthcare professionals and patients on the issue of expanding access to medicines. At…

Serbia Marija Krstic, general manager of GSK Serbia and Montenegro, discusses how the various positions she has undertaken during her 13-year career at GSK help inform her current role, the initiatives that GSK Serbia is involved in to increase access to innovative medicines for Serbian patients, and her push to ensure…

Brazil Alexei Kolchin, general manager of GSK Brazil, discusses adapting to Brazil, having previously held the equivalent role in Russia, the Brazilian affiliate’s contribution to GSK’s global growth, and its embrace of digitally disruptive technologies. Before being appointed GM of GSK in Brazil, you were the GM for GSK Russia, so…